Asset
Sparsentan
Ligand Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00635232 | phase2 | completed | 2008-03-01 | 2008-11-01 | Ligand Pharmaceuticals | A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension |
| NCT00522925 | phase2 | completed | 2007-08-01 | 2008-04-01 | Ligand Pharmaceuticals | A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension |
FDA applications (0)
This company has no applications containing this asset.